SOPHiA GENETICS SA (NASDAQ:SOPH) Shares Acquired by Federated Hermes Inc.

Key Points

• Federated Hermes Inc. increased its holdings in SOPHiA GENETICS by 89% in Q1, now owning 189,000 shares worth $627,000.
• Other institutional investors, including Millennium Management and Ridgewood Investments, also boosted their stakes, contributing to a total institutional ownership of 31.59% in the company.
• SOPHiA GENETICS reported earnings of $0.33 per share for the last quarter, significantly exceeding analyst expectations of a loss, with revenues reaching $18.32 million.

Federated Hermes Inc. increased its stake in shares of SOPHiA GENETICS SA (NASDAQ:SOPH - Free Report) by 89.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 189,000 shares of the company's stock after purchasing an additional 89,000 shares during the quarter. Federated Hermes Inc. owned 0.28% of SOPHiA GENETICS worth $627,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. Dimensional Fund Advisors LP lifted its holdings in SOPHiA GENETICS by 23.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 21,619 shares of the company's stock valued at $68,000 after acquiring an additional 4,115 shares during the period. Silverberg Bernstein Capital Management LLC lifted its holdings in SOPHiA GENETICS by 54.4% in the first quarter. Silverberg Bernstein Capital Management LLC now owns 34,675 shares of the company's stock valued at $115,000 after acquiring an additional 12,211 shares during the period. Ridgewood Investments LLC lifted its holdings in SOPHiA GENETICS by 1,930.5% in the first quarter. Ridgewood Investments LLC now owns 40,610 shares of the company's stock valued at $135,000 after acquiring an additional 38,610 shares during the period. Bank Pictet & Cie Europe AG lifted its holdings in SOPHiA GENETICS by 14.4% in the first quarter. Bank Pictet & Cie Europe AG now owns 255,200 shares of the company's stock valued at $847,000 after acquiring an additional 32,200 shares during the period. Finally, Millennium Management LLC lifted its holdings in SOPHiA GENETICS by 6.5% in the fourth quarter. Millennium Management LLC now owns 698,634 shares of the company's stock valued at $2,180,000 after acquiring an additional 42,689 shares during the period. 31.59% of the stock is owned by institutional investors and hedge funds.

SOPHiA GENETICS Price Performance

SOPHiA GENETICS stock traded up $0.03 during midday trading on Tuesday, reaching $3.04. The company's stock had a trading volume of 33,876 shares, compared to its average volume of 76,520. SOPHiA GENETICS SA has a fifty-two week low of $2.58 and a fifty-two week high of $4.92. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.21 and a current ratio of 3.39. The stock's 50 day simple moving average is $3.23 and its 200 day simple moving average is $3.25. The firm has a market capitalization of $205.11 million, a PE ratio of -6.95 and a beta of 1.00.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $0.33 EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.58. SOPHiA GENETICS had a negative return on equity of 30.69% and a negative net margin of 40.99%. The company had revenue of $18.32 million during the quarter, compared to the consensus estimate of $17.49 million. On average, equities research analysts forecast that SOPHiA GENETICS SA will post -0.96 earnings per share for the current year.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.